NCT04765722View on ClinicalTrials.gov

Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

November 12, 2024

Study Completion Date

November 12, 2024

Conditions
Chronic CoughEosinophilic BronchitisAsthma
Interventions
DRUG

Mepolizumab

Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.

DRUG

Normal Saline

Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.

Trial Locations (1)

L8S 4L8

McMaster University, Hamilton

All Listed Sponsors
collaborator

University of Manchester

OTHER

lead

McMaster University

OTHER

NCT04765722 - Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases | Biotech Hunter | Biotech Hunter